Clinical Trials Logo
  1. Home
  2. Breakthrough Cancer Pain
  3. NCT01045603

Instanyl® Non-Interventional Study — INIS  

Breakthrough Cancer Pain Clinical Trial

Official title:
A 3 Month Observational Prospective Patient Cohort Study of the Treatment of Breakthrough Pain in Cancer Patients With Instanyl®

Clinical Trial Summary

The aim of this study is to describe the use of Instanyl® (Intranasal fentanyl spray) in the treatment of breakthrough pain (BTP) in cancer patients by success of dose titration and distribution of dose strength. Data will be collected at three different time points over a 3 month period.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01045603
Study type Observational
Source Takeda
Contact
Status Completed
Phase N/A
Start date December 2009
Completion date April 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Recruiting NCT01693328 - Patient Satisfaction and Quality of Life Impact - PecFent® N/A
Recruiting NCT01698645 - Patient Satisfaction and Quality of Life Impact - PecFent® N/A
Completed NCT01936636 - Observational Registry Study of Quality of Life When Treating BTcP With Abstral N/A
Completed NCT05531422 - Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP Phase 2
Completed NCT03669263 - A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan N/A
Completed NCT02899884 - Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
Recruiting NCT03564548 - Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain Phase 2
Not yet recruiting NCT04713189 - Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain Phase 1/Phase 2
Completed NCT03895762 - Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
Terminated NCT01439919 - A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain Phase 2
Recruiting NCT00822614 - Safety of Fentanyl TAIFUN Treatment Phase 3
Terminated NCT04468490 - Treatment of Breakthrough Cancer Pain According to European Guidelines